(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -3.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Macrogenics's revenue in 2026 is $157,082,000.On average, 8 Wall Street analysts forecast MGNX's revenue for 2026 to be $4,919,658,594, with the lowest MGNX revenue forecast at $685,210,466, and the highest MGNX revenue forecast at $8,863,241,871. On average, 5 Wall Street analysts forecast MGNX's revenue for 2027 to be $5,472,022,133, with the lowest MGNX revenue forecast at $4,048,970,935, and the highest MGNX revenue forecast at $6,567,341,868.
In 2028, MGNX is forecast to generate $9,622,185,560 in revenue, with the lowest revenue forecast at $3,737,511,632 and the highest revenue forecast at $14,562,947,111.